| |
Pfizer Clarification: Roche Viracept Recall
|
| |
| |
June 6, 2007
Roche announced today that they recalled Viracept 250 mg tablet formulation and powder due to chemical impurity. Roche has commercialization rights to Viracept everywhere other than the US, Canada, US territories and possessions, and Japan.
This recall does not apply to the U.S., Canada, U.S. territories and possessions, or Japan. Pfizer separately manufactures and commercially markets Viracept at 625 mg and 250 mg formulations in the U.S., Canada and U.S. territories and possessions. Pfizer has a separate manufacturing process and manufacturing plants.
Additionally, Pfizer manufactures Viracept tablets for Japan Tobacco under a license agreement and that market is not affected by this recall.
If patients have any questions, they should consult their physician.
Physicians with questions should contact
www.pfizerpro.com/viracept
|
|
| |
| |
|
|
|
